Atopic dermatitis
CLDXCelldex Therapeutics, Inc.Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Barzolvolimab (CDX-0159) (KIT receptor) in Atopic dermatitis. The expected timing is based on the latest available company guidance and may change.
12/19/24- Initiated trial. 8/7/25- Enrollment ongoing. 11/10/25:- Enrollment ongoing in Ph2 AD study; initial efficacy data expected H2 2026. 12/09/25:- Phase 2 atopic dermatitis study reiterated as ongoing; initial efficacy data still expected H2 2026. 02/25/26:- Ph2 AD enrollment completed; topline data planned for late 2026. 05/07/26:- Phase 2 AD study enrollment complete; topline efficacy and safety results still expected late 2026. 08/06/26:- Ph2 AD topline data still expected late 2026.
Verification
Confirm timing and program details against the company announcement or filing.